Lidds AB 

LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden.